A New Dawn in the Fight Against Molecularly Driven Cancers
In the past, people referred to “curing cancer” as an unrealistic goal, a euphemism for things that couldn’t be conceived or achieved. But treating cancer becomes less mysterious every day, and today Ignyta is writing a new story, identifying the genomic causes of cancer and creating targeted cancer drugs that attack cancer at its source. Ignyta’s combination of precision therapeutics (Rx) and molecular diagnostics (Dx) creates a powerful “Rx/Dx” approach that excels at identifying and targeting hard-to-treat cancers in hard-to-find patients.
More than just a cancer drug company, Ignyta is a leader in biotechnology and precision medicine for cancer, working with healthcare providers to change the way we think about cancer, creating targeted therapies for genomically caused cancers, and putting powerful tools in the hands of those who need it most – ultimately bringing hope – and a new future – to patients with cancer.